title: [Anticoagulants after acute ischemic stroke with atrial fibrillation].
abstract: Early or delayed onset of oral anticoagulant therapy in patients with acute ischemic stroke with atrial fibrillation is an unsolved issue. Retrospectively, 294 patient records at two hospitals were scrutinized according to a protocol consisting of 20 items regarding choice of therapy (warfarin or NOAC), time for onset of therapy, CT findings of bleeding, capacity to swallow, and occurrence of clinical deterioration during the acute phase. Out of 249 patients who survived the acute phase, 116 (47%) patients were given a new prescription of warfarin or NOAC at discharge, while 43 (17 %) continued with anticoagulant therapy already prescribed before the onset of stroke. The median value for new prescriptions in relation to stroke admission was 5 days. The pattern was similar for warfarin and NOAC. Patients in whom anticoagulant therapy was started early were characterized by good capacity to swallow and no signs of bleeding on initial CT. The question »early or delayed onset of oral anticoagulant therapy after acute ischemic stroke with atrial fibrillation« needs to be tested in a randomized clinical trial.
authors.affiliation: - Uppsala, Sweden Uppsala universitet - Institutionen för medicinska vetenskaper Uppsala, Sweden.
authors.forename: Andreas
authors.initials: A
authors.lastname: Terent
authors.affiliation: Akademiska sjukhuset - Strokeenheten Uppsala, Sweden Akademiska sjukhuset - Strokeenheten Uppsala, Sweden.
authors.forename: Signild
authors.initials: S
authors.lastname: Åsberg
authors.affiliation: Akademiska sjukhuset - Kardiologkliniken Uppsala, Sweden Akademiska sjukhuset - Kardiologkliniken Uppsala, Sweden.
authors.forename: Jonas
authors.initials: J
authors.lastname: Oldgren
authors.affiliation: Akademiska sjukhuset - Kardiologkliniken Uppsala, Sweden Akademiska sjukhuset - Kardiologkliniken Uppsala, Sweden.
authors.forename: Ziad
authors.initials: Z
authors.lastname: Hijazi
authors.affiliation: Lunds universitet - Institutionen för kliniska vetenskaper, avdelningen för neurologi Lund, Sweden - .
authors.forename: Bo
authors.initials: B
authors.lastname: Norrving
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage* / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000453:epidemiology; D002543:Cerebral Hemorrhage / Q000453:epidemiology; D000069604:Dabigatran / Q000008:administration & dosage / Q000627:therapeutic use; D003680:Deglutition Disorders / Q000453:epidemiology; D006801:Humans; D008499:Medical Records; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D018570:Risk Assessment; D000069552:Rivaroxaban / Q000008:administration & dosage / Q000627:therapeutic use; D020521:Stroke / Q000188:drug therapy* / Q000453:epidemiology; D013997:Time Factors; D061665:Time-to-Treatment; D016896:Treatment Outcome; D014859:Warfarin / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D000069552:Rivaroxaban; D000069604:Dabigatran